150 related articles for article (PubMed ID: 35389319)
1. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms.
Brudno JN; Natrakul D; Lam N; Dulau-Florea A; Yuan CM; Kochenderfer JN
Leuk Lymphoma; 2022 Aug; 63(8):1849-1860. PubMed ID: 35389319
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Wesson W; Ahmed N; Rashid A; Tabak C; Logan E; Marchena-Burgos J; Nelson M; Davis JA; McGann M; Shune L; Hoffmann M; Abdallah AO; Hashmi H
Eur J Haematol; 2024 Apr; 112(4):538-546. PubMed ID: 38044594
[TBL] [Abstract][Full Text] [Related]
3. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
4. Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective.
Si X; Gu T; Liu L; Huang Y; Han Y; Qian P; Huang H
Cancer Lett; 2022 Dec; 550():215920. PubMed ID: 36122628
[TBL] [Abstract][Full Text] [Related]
5. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
Read JA; Rouce RH; Mo F; Mamonkin M; King KY
Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.
Davis JA; Sborov DW; Wesson W; Julian K; Abdallah AO; McGuirk JP; Ahmed N; Hashmi H
Transplant Cell Ther; 2023 Sep; 29(9):567-571. PubMed ID: 37225044
[TBL] [Abstract][Full Text] [Related]
8. Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.
Li Z; Que Y; Wang D; Lu J; Li C; Xu M; Wang Z; Yu Q; Long X; An N; Xiao Y; Li C
Thromb Res; 2023 Jul; 227():62-70. PubMed ID: 37235950
[TBL] [Abstract][Full Text] [Related]
9. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Juluri KR; Wu QV; Voutsinas J; Hou J; Hirayama AV; Mullane E; Miles N; Maloney DG; Turtle CJ; Bar M; Gauthier J
Blood Adv; 2022 Apr; 6(7):2055-2068. PubMed ID: 34666344
[TBL] [Abstract][Full Text] [Related]
10. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias.
Gomez-Lumbreras A; Mercadal Vilchez S; Villa-Zapata L; Malone DC; Couriel DR
Leuk Lymphoma; 2023 Dec; 64(13):2071-2080. PubMed ID: 37708442
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
[TBL] [Abstract][Full Text] [Related]
13. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.
Wang L; Hong R; Zhou L; Wang Y; Lv Y; Ni F; Zhang M; Zhao H; Ding S; Chang AH; Xu H; Hu Y; Wei G; Huang H
Cytotherapy; 2023 Feb; 25(2):192-201. PubMed ID: 36496302
[TBL] [Abstract][Full Text] [Related]
14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy.
Kitamura W; Asada N; Naoi Y; Abe M; Fujiwara H; Ennishi D; Nishimori H; Fujii K; Fujii N; Matsuoka KI; Yoshino T; Maeda Y
Br J Haematol; 2023 Jul; 202(2):294-307. PubMed ID: 36890790
[TBL] [Abstract][Full Text] [Related]
16. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.
Xia Y; Zhang J; Li J; Zhang L; Li J; Fan L; Chen L
Ann Med; 2022 Dec; 54(1):2951-2965. PubMed ID: 36382675
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Jain T; Knezevic A; Pennisi M; Chen Y; Ruiz JD; Purdon TJ; Devlin SM; Smith M; Shah GL; Halton E; Diamonte C; Scordo M; Sauter CS; Mead E; Santomasso BD; Palomba ML; Batlevi CW; Maloy MA; Giralt S; Smith E; Brentjens R; Park JH; Perales MA; Mailankody S
Blood Adv; 2020 Aug; 4(15):3776-3787. PubMed ID: 32780846
[TBL] [Abstract][Full Text] [Related]
18. Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapy.
Yeung CCS; Woolston DW; Wu V; Voutsinas JM; Basom R; Davis C; Hirayama AV; Naresh KN
Eur J Haematol; 2024 Jan; 112(1):111-121. PubMed ID: 37526606
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.
Beyar-Katz O; Perry C; On YB; Amit O; Gutwein O; Wolach O; Kedar R; Pikovsky O; Avivi I; Gold R; Ben-Ezra J; Shasha D; Ami RB; Ram R
Ann Hematol; 2022 Aug; 101(8):1769-1776. PubMed ID: 35731278
[TBL] [Abstract][Full Text] [Related]
20. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
Nagle SJ; Murphree C; Raess PW; Schachter L; Chen A; Hayes-Lattin B; Nemecek E; Maziarz RT
Am J Hematol; 2021 Apr; 96(4):455-461. PubMed ID: 33529419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
